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Objectives: As brain tumours and their treatment may
theoretically have a poorer prognosis in inflammatory
central nervous system diseases such as multiple
sclerosis (MS), all-cause mortality following a brain
tumour diagnosis was compared between patients with
and without MS. The potential role of age at tumour
diagnosis was also examined.
Setting: Hospital inpatients in Sweden with
assessment of mortality in hospital or following
discharge.
Participants: Swedish national registers identified
20 543 patients with an MS diagnosis (1969–2005)
and they were matched individually to produce a
comparison cohort of 204 163 members of the general
population without MS. Everyone with a primary brain
tumour diagnosis was selected for this study: 111 with
MS and 907 without MS.
Primary and secondary outcome measures:
5-year mortality risk following brain tumour diagnosis
and age at brain tumour diagnosis.
Results: A non-statistically significant lower mortality
risk among patients with MS (lower for those with
tumours of high-grade and uncertain-grade malignancy
and no notable difference for low-grade tumours)
produced an unadjusted HR (and 95% CI) of 0.75
(0.56 to 1.02). After adjustment for age at diagnosis,
grade of malignancy, sex, region of residence and
socioeconomic index, the HR is 0.91 (0.67–1.24). The
change in estimate was largely due to adjustment for
age at brain tumour diagnosis, as patients with MS
were on average 4.7 years younger at brain tumour
diagnosis than those in the comparison cohort
(p<0.001).
Conclusions: Younger age at tumour diagnosis may
contribute to mortality reduction in those with high-
grade and uncertain-grade brain tumours. Survival
following a brain tumour is not worse in patients with
MS; even after age at brain tumour diagnosis and
grade of malignancy are taken into account.
INTRODUCTION
It has been reported that brain tumours are
diagnosed more frequently in patients with
multiple sclerosis (MS) than among the
general population, despite an overall reduc-
tion in cancer risk in MS.1 An earlier study
using the same material as used here identi-
ﬁed an increase in the detection of brain
tumours of low-grade rather than high-grade
malignancy in Swedish patients with MS.
Some of the increased frequency of brain
tumours may have been due to relatively fre-
quent neuroimaging of the central nervous
system (CNS) in patients with MS, resulting
in an increased tumour detection rate,
including for asymptomatic tumours.1
Despite the apparently lower proportion of
high-grade brain tumour types in MS,2 prog-
nosis following a brain tumour diagnosis in
patients with an inﬂammatory degenerative
disease of the CNS remains a concern. It has
been suggested that associated treatments
including brain surgery, radiotherapy and
chemotherapy may be relevant to the course
of MS: it is plausible that surgery and
radiotherapy result in the liberation of
brain-speciﬁc antigens that might promote
autoimmunity and thus adversely inﬂuence
the disease course in MS.2 We therefore
investigated mortality following a ﬁrst brain
tumour diagnosis in patients with MS, com-
pared with people without MS who also had
a ﬁrst brain tumour diagnosis; MS disease
course may inﬂuence mortality, but this study
was not able to investigate this putative medi-
ating factor, and examined mortality as the
Strengths and limitations of this study
▪ The majority of patients with multiple sclerosis
(MS) who had brain tumours during the study
period were included and compared with patients
with brain tumours who did not have MS.
▪ Use of all-cause mortality identifies as an unam-
biguous end-point, but the specific mechanism
is not identified.
▪ Information on brain tumour stage and size at
diagnosis was not available.
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ﬁnal outcome. Age at ﬁrst brain tumour diagnosis as an
explanatory factor for variation in mortality risk was also
investigated.
This study utilises a cohort of Swedish patients with
MS and a matched general population comparison
cohort.1 The analysis presented here is based on the
minority subset from each cohort with a primary brain
tumour and mortality among these patients is the main
outcome.
PATIENTS AND METHODS
The individuals included in this study were drawn from
two larger Swedish cohorts, described previously.1
Diagnoses of MS between 1969 and 2005 were identiﬁed
using the National Inpatient Register3 and the National
Swedish Multiple Sclerosis Register.4 The original study
design was that patients with MS were individually
matched with 12 individuals (a lower number was
achieved in a minority) by year of birth, sex, vital status
and region of residence, at the time of diagnosis in the
matched case. The Total Population Register provided
information on date of death or migration. The National
Swedish Cancer Register5 identiﬁed cancer diagnoses,
and brain tumours were classiﬁed as high malignancy,
low malignancy and uncertain level of malignancy
(table 1). A six-category socioeconomic index was based
on occupation identiﬁed from the census nearest in time
to study entry (manual workers, non-manual workers,
professionals, self-employed, farmers and others).
From among the original 20 543 with and 204 163
without MS, we excluded 479 (267 with MS) due to
missing information. We then identiﬁed all those with a
brain tumour who did not have a prior cancer diagnosis
at any other site. A total of 111 with MS and 907 without
had a primary brain tumour diagnosis and comprises
the main study population examined here. A further
post hoc analysis extended the sample to those with
either a primary brain tumour or a primary spinal cord
tumour, increasing numbers to 124 with MS and 949
without MS.
Statistical analysis
Cox regression was used to estimate mortality risk in the
5 years following brain tumour diagnoses in patients
with MS compared with the reference cohort. Follow-up
was from brain tumour diagnosis to death, emigration,
5 years duration or 31 December 2005, whichever
occurred ﬁrst. Adjustment was for age at brain tumour
diagnosis (continuous), level of malignancy, sex, geo-
graphical region (Northern, Central and Southern
Sweden) and socioeconomic index. Further analyses
were stratiﬁed by grade of malignancy. Mortality risk for
10 years was also examined and a Kaplan-Meier curve
was produced. The proportionality of hazards assump-
tion was veriﬁed for all analyses.
Table 1 Brain tumour distribution
Tumour classification| PAD code
Number of participants (N=1008)
MS No MS
N=110 (%) N=898 (%)
Low grade malignancy
Plexiform neurofibroma/hamartoma 451 7 (6.4) 52 (5.8)
Meningioma, benign 461 33 (30.0) 251 (28.0)
Astrocytoma (grades 0–2) 475 10 (9.1) 130 (14.5)
Ependymoma (grades 1–2) 485 2 (1.8) 9 (1.0)
Hemangioblastoma 511 1 (0.9) 6 (0.7)
Dermoid cyst, cholesteatoma, teratoma 821 0 (0) 2 (0.2)
Craniopharyngioma 881 3 (2.7) 8 (0.9)
Germinoma 981 2 (1.8) 2 (0.2)
High-grade malignancy
Neuroblastoma 416 0 (0) 4 (0.5)
Medulloblastoma 436 1 (0.9) 4 (0.5)
Neurinoma 456 1 (0.9) 1 (0.1)
Astrocytoma (grades 3–4) 476 28 (25.5) 314 (35.0)
Ependymoblastoma (grades 3–4) 486 1 (0.9) 0 (0)
Meningioma 466 1 (0.9) 9 (1.0)
Teratoma 826 0 (0) 1 (0.1)
Uncertain grade of malignancy
Neurinoma 453 0 (0) 1 (0.1)
Hemangioma 501 2 (1.8) 13 (1.5)
Neuroepithelial tumour 991 10 (9.1) 42 (4.7)
Hemangiopericytoma, NOS 533 0 (0) 1 (0.1)
Other 8 (7.3) 48 (5.3)
MS, multiple sclerosis; NOS, not otherwise specified; PAD, pathological and anatomical diagnosis.
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To examine whether the results are inﬂuenced sub-
stantially by immunomodulatory therapy, the follow-up
period was right truncated to end before 1996, when the
ﬁrst of the more recent therapies, interferon β, was
introduced.6
A further post-hoc analysis included patients with a
primary spinal cord tumour, in addition to those with
primary brain tumours.
To investigate variation in age at brain tumour diagno-
sis, age was the dependent variable in linear regression
analysis. Adjustment was for level of malignancy, sex,
geographical region and socioeconomic index.
The analysis used SPSS statistical software, version 21.
RESULTS
Table 1 reports the distribution of brain tumour types in
those with and without MS. As previously reported,2 a
lower proportion of those with MS had tumours of high-
grade malignancy compared with the non-MS cohort.
The proportions in the three broad grade categories
(high, low and uncertain malignancy) are also shown in
table 2. Table 2 reports other characteristics of the study
population. There was a lower mortality risk in the 5 years
following brain tumour diagnosis among patients with
MS, which approached statistical signiﬁcance before, but
not after adjustment (table 2 and ﬁgure 1). Adjustment
for age at cancer diagnosis accounts for the change in
estimates. Figure 1 demonstrates that a similar pattern of
association continues after 5 years of follow-up.
When stratiﬁed by grade of malignancy, there is no dif-
ference in mortality by MS for the low-grade malignancy
group. There is a lower mortality risk in patients with MS
among those with high-grade and undetermined-grade
tumours. The association was observed to be statistically
signiﬁcant among patients with undetermined-grade
tumours, but adjustment for the potential confounding
factors eliminated this signiﬁcance. Although not statistic-
ally signiﬁcant, a lower mortality risk remained among
patients with MS.
Right truncation of the follow-up period to before
1996 did not alter the ﬁndings notably, producing
unadjusted and adjusted HRs (with 95% CIs) for the
association of MS with mortality of 0.67 (0.46 to 0.98;
p=0.037) and 0.79 (0.54 to 1.16; p=0.234), respectively.
Addition of patients with a primary spinal cord
tumour to the main analysis did not alter the results dra-
matically, producing unadjusted and adjusted HRs for
mortality associated with MS of 0.68 (0.50–0.93;
p=0.014) and 0.80 (0.58–1.09; p=0.161), respectively.
Linear regression indicated patients with MS were on
average 4.7 years younger at brain tumour diagnosis,
after adjustment for the potential confounding factors
(p<0.001).
Table 2 Five-year mortality following a brain tumour diagnosis among patients with and without multiple sclerosis (MS)
Events/patients (%) Unadjusted Adjusted*
MS No MS
HR (95% CI) p Value HR (95% CI) p ValueN=110 (10.9%) N=898 (89.1%)
Unstratified
Cohort
No MS – 478/898 Reference
MS 45/110 – 0.75 (0.56 to 1.02) 0.070 0.91 (0.67 to 1.24) 0.554
Age (years) 49.6† 52.3† 1.04 (1.04 to 1.05) <0.001 1.05 (1.04 to 1.05) <0.001
Sex
Male 25/44 (40.0) 177/283 (31.5) Reference Reference
Female 20/66 (60.0) 301/615 (68.5) 0.65 (0.55 to 0.78) <0.001 0.89 (0.74 to 1.07) 0.201
Brain tumour histological classification
Low grade 17/58 (52.7) 131/460 (51.2) Reference Reference
High grade 22/32 (29.1) 284/333 (37.1) 4.76 (3.89 to 5.82) <0.001 5.11 (4.14 to 6.31) <0.001
Uncertain grade 6/20 (18.2) 63/105 (11.7) 2.44 (1.83 to 3.25) <0.001 2.47 (1.85 to 3.30) <0.001
Stratified by brain tumour histology
Low grade
No MS – 131/460 Reference Reference
MS 17/58 – 1.10 (0.66 to 1.82) 0.722 1.14 (0.68 to 1.89) 0.618
High grade
No MS – 284/333 Reference Reference
MS 22/32 – 0.75 (0.49 to 1.16) 0.200 0.91 (0.58 to 1.42) 0.665
Uncertain grade
No MS – 63/105 Reference Reference
MS 6/20 – 0.39 (0.17 to 0.89) 0.026 0.67 (0.27 to 1.68) 0.394
*HRs adjusted for age at brain tumour diagnosis, level of malignancy, sex, region of residence and socioeconomic index.
†Mean age in years (HRs are for each 1-year increase in age).
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DISCUSSION
This study compared Swedish patients with MS who
received a primary brain tumour diagnosis between
1969 and 2005, with MS-free members of the general
population also with a primary brain tumour. Patients
with MS who have brain tumours did not have a raised
mortality risk compared with brain tumour patients
without MS. The patients with MS tended to have fewer
high-grade malignancies as previously described,2 and
on average were diagnosed at an earlier age. Even after
taking into account age at tumour diagnosis and grade
of malignancy, there is no evidence of a further raise in
mortality risk associated with brain tumours in patients
with MS.
It is plausible that brain tumours may have a worse
prognosis in patients with an inﬂammatory disease of
the CNS and it has been suggested that treatment for
brain tumours may have adverse implications for MS
disease course.2 Although we were unable to examine
alterations in MS disease course here and did not have
information on changes in MS phenotype, we assessed
mortality as a possible consequence. Mortality is a plaus-
ible outcome as patients with MS have a higher risk of
fatal comorbidity from a variety of causes including
infections7 and cardiovascular disease.8 In general,
patients with MS may have shorter life expectancy than
the general population9 10 with an average of approxi-
mately 5–10 years of life lost.11 Mortality has been identi-
ﬁed as an unambiguously valid outcome relevant to MS
severity and disease progression, including through
causes of death such as suicide which is more common
among patients with MS, thus emphasising the import-
ance of considering all-cause mortality as the outcome.12
The results of our analyses indicate that brain tumours
and associated treatment are not greater mortality risks
in patients with MS than in patients without MS who
have brain tumours. When the analysis was extended to
include patients with primary spinal cord tumours, as
well as brain tumours, the results were not notably
altered and did not suggest an increased mortality risk
among patients with MS.
Earlier age at brain tumour diagnosis appears to help
explain some of the observed lower mortality risk, con-
sistent with more frequent neuroimaging in patients
with MS enhancing tumour detection rates. While this
will result in a higher diagnosis rate for the asymptom-
atic tumours of low-grade malignancy reported here and
as previously described,2 it will also result in an earlier
diagnosis of high-grade malignant tumours: this is con-
sistent with evidence of reduction in mortality risk for
patients with MS with high-grade and uncertain-grade
tumour types. The magnitude of the inverse association
is attenuated by the adjustment for age at diagnosis.
Another non-mutually exclusive possibility is that brain
tumour onset occurs at a younger age among patients
with MS. Despite the role of detection or onset at a
younger age, there was still no evidence of increased
mortality risk in patients with MS, even after earlier age
at diagnosis and tumour grade were taken into account
through statistical adjustment.
Although it is not possible to provide a precise propor-
tion, we believe this study will have identiﬁed the major-
ity of patients with MS with a primary brain tumour
diagnosed and treated during the study period. The
patient register identiﬁed inpatient diagnoses for most
of the study period (with outpatient diagnoses from
2001), and some patients with MS who were not inpati-
ents will not have been included in the larger original
MS cohort. However, as the cancer register is over 99%
complete, virtually all brain tumour diagnoses will have
been recorded and most of these patients will have been
admitted to hospital for treatment. This will have
resulted in comorbid diagnoses, such as MS, being
included in the patient register and thus the likely inclu-
sion of such patients in our MS cohort.
Potential limitations of this study include lack of
knowledge about tumour stage or size at diagnosis, but
the ﬁndings are consistent with earlier stage and smaller
tumour size in patients with MS due to earlier detection.
It was not possible to assign a malignancy grade to all
tumours, but some reduction of mortality risk was seen
in the high-grade as well as uncertain grade categories.
We restricted the main results to deaths that occurred
during the ﬁrst 5 years after diagnosis when tumour-
related adverse sequelae are most likely to occur; but the
ﬁndings were similar for longer follow-up. To help
explain the results it would have been useful to examine
MS disease course in greater detail, particularly changes
in MS phenotype: unfortunately such longitudinal
Figure 1 Mortality following a brain tumour diagnosis among
patients with and without multiple sclerosis. Patients with brain
tumours were followed for up to 10 years from their diagnosis
and treatment. The Kaplan-Meier curves indicate mortality
risk, divided into those with and without multiple sclerosis.
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information on phenotype was not available to us. It was
not possible to examine inﬂuences of more recently
introduced immunomodulatory therapy, as these data
were not available from the registers for this study
period. To tackle this, we performed a post hoc analysis
with right truncation, so that follow-up was ended prior
to introduction of the ﬁrst of such therapies, interferon
β, which began to be used in Sweden in 1996.6 While
this does not directly test the possible inﬂuence of these
therapies, the results show that they did not have a
major inﬂuence on the overall ﬁndings. Another poten-
tial limitation is our lack of access to reliable information
on the number of MRI scans performed. While we
hypothesise that such procedures may enhance earlier
tumour detection in patients with MS, we cannot
conﬁrm this using these data.
Earlier detection due to more frequent MS-related
CNS investigations may contribute to reduced mortality
risk for high-grade tumours. Even after age at diagnosis
and malignancy grade are taken into account, brain
tumours in patients with MS are not associated with
higher mortality than in patients without MS, indicating
that neither tumours nor their treatment are more likely
to be fatal in this patient group.
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